INCI
INCI NAMEv2.0
enkozhja
原料辞典検索/polymethylsilsesquioxane/POLYMETHYLSILSESQUIOXANE
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

POLYMETHYLSILSESQUIOXANE

標準 INCI 準拠: POLYMETHYLSILSESQUIOXANE
白濁剤
[EU CosIng Official Definition] Polymer formed by hydrolysis and condensation of methyltrimethoxysilane
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における POLYMETHYLSILSESQUIOXANE のグローバル配合基準と処方特性とは？

POLYMETHYLSILSESQUIOXANE（CAS番号: 68554-70-1）は、化粧品処方において主に白濁剤として配合される原料です。日本厚労省/JCIA（規制なし）、韓国MFDS（規制なし）、欧州CosIng（規制なし）など6大法域の法定基準下で管理され、通常 2–15%（適正安定域 pH 4–8）で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for POLYMETHYLSILSESQUIOXANE
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)POLYMETHYLSILSESQUIOXANE (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)Former KR Nomenclature Redirect Active—
③ 欧州連合 (EU CosIng EC 1223/2009)POLYMETHYLSILSESQUIOXANE
④ 米国一般化粧品 (US PCPC / MoCRA INCI)POLYMETHYLSILSESQUIOXANE
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)聚甲基倍半硅氧烷
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)POLYMETHYLSILSESQUIOXANE (標準INCI参照 · 任意カタカナ音訳排除)

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for POLYMETHYLSILSESQUIOXANE
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #3962
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Aqueous Serum / Ampoulen=19
Min 2% · Q1 4% · Median 5% · Q3 5% · Max 15%
Emulsion / Creamn=33
Min 2% · Q1 2% · Median 4% · Q3 5% · Max 10%
Sunscreen / Colorn=47
Min 1% · Q1 3% · Median 5% · Q3 5.85% · Max 12%
Aqueous Serum / Ampoule — Aqueous serum, toner & hydrogel matrix formulation component
Verified Source: Global Starter Formulation Library Statistical Distribution (n=19, GRANT 19) (cir_safety) · GRANT 19
Typical Median: 5%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for POLYMETHYLSILSESQUIOXANE
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 A — 水성化粧水・美容液・アンプル2% · 4% · 5% · 5% · 15%Aqueous serum, toner & hydrogel matrix formulation componentGlobal Starter Formulation Library Statistical Distribution (n=19, GRANT 19)
剤形群 B — 乳液・エマルジョン・クリーム2% · 2% · 4% · 5% · 10%Emulsion cream & lotion structural / conditioning agentGlobal Starter Formulation Library Statistical Distribution (n=33, GRANT 33)
剤形群 D — 日焼け止め (UV)・メイクアップ・ファンデーション1% · 3% · 5% · 5.85% · 12%Sun care & color cosmetics dispersion / sensory modifierGlobal Starter Formulation Library Statistical Distribution (n=47, GRANT 47)
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Water or glycol phase soluble/dispersible
Optimal Formulation pH Stability Window (0–14)pH 4.0 – 8.0
0245.5791114

Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ GLYCERIN+ CAPRYLIC/CAPRIC TR…+ TOCOPHEROL✕ Verify phase compati…POLYMETHYLSILSESQU…
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

+ GLYCERIN+ CAPRYLIC/CAPRIC TRIGLYCERIDE+ TOCOPHEROL
代表商品名参考 (商標法第90条第1項第2号 記述的表示)
POLYMETHYLSILSESQUIOXANE

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: POLYMETHYLSILSESQUIOXANE | CAS No.: 68554-70-1 | EC No.: N/A - Origin: SYNTHETIC | Functions: - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [POLYMETHYLSILSESQUIOXANE] · EU [POLYMETHYLSILSESQUIOXANE] · CN [聚甲基倍半硅氧烷] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Polymer formed by hydrolysis and condensation of methyltrimethoxysilane Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 3962 (聚甲基倍半硅氧烷)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): Quantum satis (QS) within standard cosmetic safety margins ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [aqueous_serum] Typical range: 2.0 ~ 15.0% (Median 5.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=19, GRANT 19)) — Aqueous serum, toner & hydrogel matrix formulation component - [emulsion_cream] Typical range: 2.0 ~ 10.0% (Median 4.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=33, GRANT 33)) — Emulsion cream & lotion structural / conditioning agent - [sun_color] Typical range: 1.0 ~ 12.0% (Median 5.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=47, GRANT 47)) — Sun care & color cosmetics dispersion / sensory modifier ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: POLYMETHYLSILSESQUIOXANE ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 25427646 (2014, Biofabrication): Novel preparation of controlled porosity particle/fibre loaded scaffolds using a hybrid micro-fluidic and electrohydrody

関連査読付き学術論文 (NIH PubMed) (1)

Novel preparation of controlled porosity particle/fibre loaded scaffolds using a hybrid micro-fluidic and electrohydrodynamic technique. [PMID: 25427646 · 2014]
Parhizkar M, Sofokleous P, Stride E, Edirisinghe M · Biofabrication (2014)

The purpose of this research was to produce multi-dimensional scaffolds containing biocompatible particles and fibres. To achieve this, two techniques were combined and used: T-Junction microfluidics and electrohydrodynamic (EHD) processing. The former was used to form layers of monodispersed bovine serum albumin (BSA) bubbles, which upon drying formed porous scaffolds. By altering the T-Junction processing parameters, bubbles with different diameters were produced and hence the scaffold porosity could be controlled. EHD processing was used to spray or spin poly(lactic-co-glycolic) (PLGA), polymethysilsesquioxane (PMSQ) and collagen particles/fibres onto the scaffolds during their production and after drying. As a result, multifunctional BSA scaffolds with controlled porosity containing PLGA, PMSQ and collagen particles/fibres were obtained. Product morphology was studied by optical and scanning electron microscopy. These products have potential applications in many advanced biomedical, pharmaceutical and cosmetic fields e.g. bone regeneration, drug delivery, cosmetic cream lathers, facial scrubbing creams etc.

よくある質問 (FAQ)

Q1. POLYMETHYLSILSESQUIOXANE の各国公式全成分表示名称（7トラック）はどのように異なりますか？
日本化粧品工業連合会(JCIA)表示名称は 'POLYMETHYLSILSESQUIOXANE (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'POLYMETHYLSILSESQUIOXANE'、中国NMPA IECIC標準中国語名は '聚甲基倍半硅氧烷' です。
Q2. POLYMETHYLSILSESQUIOXANE のグローバル6大法域における法定配合基準 (Layer 1) は？
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における POLYMETHYLSILSESQUIOXANE の通常配合濃度 (Layer 3) と適正 pH は？
主要剤形 (aqueous_serum) において通常 2〜15%（中央値 5%）で配合され、適正pH範囲は 4〜8 です。
Q4. POLYMETHYLSILSESQUIOXANE の配合禁忌 (Incompatibilities) と推奨シナジー成分は？
推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。